Ahmedabad, India : Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and half year ended September 30th, 2025.
Key Financial Highlights
Q2 FY26 Highlights
- Revenue from operations at Rs. 61,232 mn, up 17% over last year.
- Research & Development (R&D) investments for the quarter stood at Rs. 4,820 mn (7.9% of revenues).
- EBITDA for the quarter was Rs. 20,158 mn, up 38% YoY. EBITDA margin for the quarter stood at 32.9%, which is an improvement of 500 bps on a YoY basis.
- Net Profit for the quarter was Rs. 12,586 mn, up 38% YoY.
- Capex (organic) for the quarter was Rs. 4,911 mn.
H1 FY26 Highlights
- Revenue from operations at Rs. 1,26,969 mn, up 11% over last year.
- R&D investments stood at Rs. 9,676 mn (7.6% of revenues).
- EBITDA was Rs. 41,043 mn, up 16% YoY. EBITDA margin stood at 32.3%, which is an improvement of 130 bps over the previous year.
- Net Profit was Rs. 27,254 mn, up 17% YoY.
- Capex (organic) for the half year was Rs. 8,931 mn.
- Net Debt to Equity ratio as on 30th September, 2025 was 0.09x while Net Debt to EBITDA stood at 0.3x at the end of September, 2025.
Consolidated Financial Results
| Rs. mn | Q2 FY26 | Q2 FY25 | % Gr. y-o-y | Q1 FY26 | % Gr. q-o-q |
| Revenue from Operations | 61,232 | 52,370 | 16.9% | 65,737 | -6.9% |
| EBITDA | 20,158 | 14,614 | 37.9% | 20,885 | -3.5% |
| EBITDA margin (%) | 32.9% | 27.9% | 31.8% | ||
| PBT | 16,874 | 12,709 | 32.8% | 19,206 | -12.1% |
| Net Profit | 12,586 | 9,112 | 38.1% | 14,668 | -14.2% |
| Rs. mn | H1 FY26 | H1 FY25 | % Gr. y-o-y |
| Revenue from Operations | 1,26,969 | 1,14,445 | 10.9% |
| EBITDA | 41,043 | 35,454 | 15.8% |
| EBITDA margin (%) | 32.3% | 31.0% | |
| PBT | 36,080 | 31,706 | 13.8% |
| Net Profit | 27,254 | 23,311 | 16.9% |
Q2 FY26 Business-wise Sales Performance (Consolidated)
Our strong performance this quarter reaffirms the power of our diversified business model and our execution capabilities across geographies and verticals. We delivered robust revenue growth and industry-leading profitability, aided by consistent outperformance in our US and India formulations businesses, sustained high growth in International Markets as well as strategic acquisitions in Wellness and MedTech. These results reflect our commitment to sustainable growth and global expansion, anchored in quality, compliance, and patient-centric innovation.Dr. Sharvil Patel, Managing Director – Zydus Lifesciences Limited
Leave a Reply